KA
ABUS icon

Kerrisdale Advisers’s Arbutus Biopharma ABUS Stock Holding History

Kerrisdale Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$429K – 42
2021
Q3 		$429K Buy
+100,000
New +$333K 0.05% 55
2021
Q2 		– Sell
-208,150
Closed -$693K – 55
2021
Q1 		$693K Buy
+208,150
New +$803K 0.05% 52
2013
Q4 		– Sell
-90,057
Closed -$626K – 55
2013
Q3 		$626K Buy
90,057
+54,497
+153% +$300K 0.29% 47
2013
Q2 		$167K Buy
+35,560
New +$168K 0.08% 58

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

Kerrisdale Advisers's ABUS Position: Q4 2021 in Review

Kerrisdale Advisers sold out of Arbutus Biopharma (ABUS) in Q4 2021, closing a stake of 100,000 shares — an estimated $429K sold.

Kerrisdale Advisers first reported a position in ABUS in Q2 2013 and held it in 4 quarters. The position peaked at $693K in Q1 2021. 122 funds tracked by Wall St. Rank hold ABUS as of Q4 2021.

  • Kerrisdale Advisers reported no remaining Arbutus Biopharma position as of Q4 2021 after selling out during the quarter.
  • Kerrisdale Advisers sold 100,000 Arbutus Biopharma shares in Q4 2021, an estimated $429K.
  • Kerrisdale Advisers first reported a position in Arbutus Biopharma in Q2 2013 and held it in 4 quarters.
  • Kerrisdale Advisers's Arbutus Biopharma position peaked at $693K in Q1 2021.
  • 122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2021.

Based on Kerrisdale Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.